Feb 26 (Reuters) - Madrigal Pharmaceuticals Inc MDGL.O:
MADRIGAL ANNOUNCES NEW TWO-YEAR DATA FROM THE COMPENSATED MASH CIRRHOSIS ARM OF THE MAESTRO-NAFLD-1 TRIAL DEMONSTRATING POTENTIAL BENEFIT OF REZDIFFRA™ (RESMETIROM) IN PATIENTS WITH COMPENSATED MASH CIRRHOSIS
MADRIGAL PHARMACEUTICALS INC - REPORTS POSITIVE TWO-YEAR RESULTS FROM PHASE 3 TRIAL
MADRIGAL PHARMACEUTICALS INC - SAFETY PROFILE OF REZDIFFRA CONSISTENT WITH OTHER TRIALS
Source text: ID:nGNXbShBP0
Further company coverage: MDGL.O